Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Xeris Biopharma Inc.

    NASDAQ: XERS · Real-Time Price · USD
    4.84
    -0.04 (-0.82%)
    At close: May 23, 2025, 3:59 PM
    4.83
    -0.21%
    After-hours: May 23, 2025, 05:11 PM EDT
    -0.82%
    Bid 4.73
    Market Cap 775.15M
    Revenue (ttm) 222.55M
    Net Income (ttm) -45.08M
    EPS (ttm) -0.29
    PE Ratio (ttm) -16.69
    Forward PE 40.62
    Analyst Strong Buy
    Ask 4.94
    Volume 969,417
    Avg. Volume (20D) 3,128,819
    Open 4.76
    Previous Close 4.88
    Day's Range 4.74 - 4.84
    52-Week Range 1.86 - 6.07
    Beta 0.91

    About XERS

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol XERS
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for XERS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    2 months ago
    +9.55%
    Xeris Biopharma shares are trading higher after th... Unlock content with Pro Subscription
    9 months ago
    +4.69%
    Xeris Biopharma shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 revenue guidance above estimates.
    news image

    4 days ago · businesswire.com

    Xeris Announces Details for Analyst & Investor Day

    CHICAGO--(BUSINESS WIRE)--Xeris Announces Details for Analyst & Investor Day.

    news image

    2 weeks ago · seekingalpha.com

    Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript

    Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve Pie...

    news image

    2 weeks ago · zacks.com

    Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates

    Xeris Biopharma (XERS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.14 per share a year ago.

    news image

    2 weeks ago · businesswire.com

    Xeris Biopharma Reports Record First Quarter 2025 Financial Results

    CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...

    news image

    2 weeks ago · seekingalpha.com

    Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings

    Xeris Biopharma Holdings, Inc. has shown consistent double-digit growth and is expected to continue this trend, with Q1 earnings projected to drive the share price higher. Key metrics to watch include...

    news image

    1 month ago · businesswire.com

    Xeris Announces Changes to Its Board of Directors

    CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative p...

    news image

    2 months ago · zacks.com

    Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?

    Xeris Biopharma (XERS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more str...

    news image

    2 months ago · seekingalpha.com

    Xeris Biopharma Holdings, Inc. (XERS) Q4 2024 Earnings Call Transcript

    Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve ...

    news image

    2 months ago · zacks.com

    Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings

    Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with W...

    news image

    2 months ago · zacks.com

    Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates

    Xeris Biopharma (XERS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.10 per share a year ago.

    Add to Watchlist